Avadel Pharmaceuticals PLC (AVDL)
Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
| Company Name: |
Avadel Pharmaceuticals PLC |
| Stock buyback: |
AVDL buyback |
| Website: |
www.avadel.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding AVDL: |
3 |
| Total Market Value Held by ETFs: |
$781703 |
| Total Market Capitalization: |
$1.64B |
| % of Market Cap. Held by ETFs: |
0.05% |
|
|
April 18, 2024 • 5:26 PM Eastern
Strong Buy (3.90 out of 4)
100th percentile
|
|
Free AVDL Email Alerts:
